Clinical Report: Retrospective Case Series on Crisaborole for Trachyonychia
Overview
This study evaluates the efficacy and safety of crisaborole in treating trachyonychia in pediatric patients. Results indicate clinical improvement in the majority of cases after 6 and 12 weeks of treatment.
Background
Trachyonychia is a chronic nail disorder predominantly affecting children, characterized by rough nail plates and longitudinal ridging. Current treatment options are limited, and many existing therapies carry risks of adverse effects, particularly in the pediatric population. Crisaborole, a nonsteroidal PDE4 inhibitor, may offer a safer alternative with its anti-inflammatory properties.
Data Highlights
Time Point
Clinical Improvement
Complete Remission
Partial Remission
6 weeks
82.1%
43.2%
38.9%
12 weeks
N/A
48.5%
N/A
Key Findings
Crisaborole was applied topically twice daily with nightly occlusion.
82.1% of nails showed significant clinical improvement at 6 weeks.
43.2% of nails achieved complete remission at 6 weeks.
48.5% of nails maintained complete remission at 12 weeks.
No severe adverse events were reported during the study.
Clinical Implications
Crisaborole may provide a treatment option for pediatric patients with trachyonychia, particularly given the limitations of existing therapies.
Conclusion
Crisaborole demonstrates efficacy and safety for treating trachyonychia in children, warranting further investigation.
